Optimal Sampling Times for Bayesian Estimation of the Pharmacokinetic Parameters of Nortriptyline During Therapeutic Drug Monitoring

被引:0
|
作者
Yann Merlé
France Mentré
机构
[1] INSERM U436,
[2] CHU Pitié-Salpêtrière,undefined
关键词
nortriptyline; Bayesian design; Bayesian estimation; information criterion; optimal sampling times; therapeutic drug monitoring;
D O I
暂无
中图分类号
学科分类号
摘要
Sampling times for Bayesian estimation of the pharmacokinetic parameters of an antidepressant drug, nortriptyline, during its therapeutic drug monitoring were optimized. Our attention was focused on designs including a limited number of measurements: one, two, and three sample designs in which sampling times had to be chosen between 0 and 24 hr after the last intake of a test-dose study. The optimization was conducted in four groups of patients defined by their gender and the administration or not of concomitant drugs inhibiting the metabolism of nortriptyline. The Bayesian design criterion was defined as the expected information provided by an experiment. A stochastic approximation algorithm, the Kiefer–Wolfowitz algorithm, was used for the criterion maximization under experimental constraints. Results showed that optimal Bayesian sampling times differ between patients in monotherapy and polytherapy. For one-sample designs the measurements have to be performed either at the lower (0 hr) or at the upper (24 hr) bound of the admissible interval. Replications were often found for 2- and 3-point designs. Other sampling designs can lead to criterion close to the optimum and can therefore be performed without great loss of information. In contrast, we found that several designs lead to low values of the information criterion, which justifies the approach.
引用
收藏
页码:85 / 101
页数:16
相关论文
共 50 条
  • [21] Evaluation of pharmacokinetic parameters of critically ill patients and simulation of dosing regimens required by Bayesian Therapeutic Drug Monitoring of fluconazole
    Matusik, E.
    Bienvenu, A. L.
    Pradat, P.
    Rimmele, T.
    Pirriou, V.
    Gagnieu, M. C.
    Parent, F.
    Tod, M.
    Leboucher, G.
    Goutelle, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 75 - 76
  • [22] BAYESIAN-ESTIMATION OF DOXORUBICIN PHARMACOKINETIC PARAMETERS
    BRESSOLLE, F
    RAY, P
    JACQUET, JM
    BRES, J
    GALTIER, M
    DONADIO, D
    JOURDAN, J
    ROSSI, JF
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 29 (01) : 53 - 60
  • [23] Population pharmacokinetic measures, their estimation and selection of sampling times
    Fedorov, Valerii
    Leonov, Sergei
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2007, 17 (05) : 919 - 941
  • [24] Therapeutic drug monitoring of nortriptyline in smoking cessation: A multistudy analysis
    Mooney, M. E.
    Reus, V. I.
    Gorecki, J.
    Hall, S. M.
    Humfleet, G. L.
    Mun, R. F.
    Delucchi, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (03) : 436 - 442
  • [25] IMPACT OF PHARMACIST SCHEDULING OF BLOOD-SAMPLING TIMES FOR THERAPEUTIC DRUG-MONITORING
    AMBROSE, PJ
    NITAKE, M
    KILDOO, CW
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1988, 45 (02): : 380 - 382
  • [26] Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation
    Monchaud, Caroline
    de Winter, Brenda C.
    Knoop, Christiane
    Estenne, Marc
    Reynaud-Gaubert, Martine
    Pison, Christophe
    Stern, Marc
    Kessler, Romain
    Guillemain, Romain
    Marquet, Pierre
    Rousseau, Annick
    CLINICAL PHARMACOKINETICS, 2012, 51 (03) : 175 - 186
  • [27] Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation
    Caroline Monchaud
    Brenda C. de Winter
    Christiane Knoop
    Marc Estenne
    Martine Reynaud-Gaubert
    Christophe Pison
    Marc Stern
    Romain Kessler
    Romain Guillemain
    Pierre Marquet
    Annick Rousseau
    Clinical Pharmacokinetics, 2012, 51 : 175 - 186
  • [28] INTRAVENOUS ADRIAMYCIN IN OUTPATIENTS - ADVANTAGES OF OPTIMIZING SAMPLING TIME TOGETHER WITH BAYESIAN-ESTIMATION OF PHARMACOKINETIC PARAMETERS
    LAUNAY, MC
    MILANO, G
    ILIADIS, A
    FRENAY, M
    BULLETIN DU CANCER, 1989, 76 (08) : 903 - 904
  • [29] Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis
    Abolhassani-Chimeh, Reihaneh
    Akkerman, Onno W.
    Saktiawati, Antonia M., I
    Punt, Nieko C.
    Bolhuis, Mathieu S.
    Subronto, Yanri W.
    Sumardi
    van der Werf, Tjip S.
    Kosterink, Jos G. W.
    Alffenaar, Jan-Willem C.
    Sturkenboom, Marieke G. G.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (07)
  • [30] Pharmacokinetic variability of valproate during pregnancy - Implications for the use of therapeutic drug monitoring
    Landmark, Cecilie Johannessen
    Farrnen, Anette Huuse
    Burns, Margrete Larsen
    Baftiu, Arton
    Lossius, Morten I.
    Johannessen, Svein I.
    Tomson, Torbjorn
    EPILEPSY RESEARCH, 2018, 141 : 31 - 37